|
|
|
CARDIOVASCULAR HEALTHNorthwestern Medicine Bluhm Cardiovascular Institute has an enduring commitment to improving the heart health of our patients through expert care, advanced education and scientific breakthroughs.
As one of the top 10 cardiology, heart and vascular surgery programs in the U.S.¹ and among the top 20 cardiac surgery programs in the world, ²we’re proud that our rankings reflect the exceptional outcomes achieved by our multidisciplinary team. Northwestern Memorial Hospital anchors this excellence as the No. 2 hospital nationally for quality and accountability.³ Over the past two decades, Northwestern Medicine Bluhm Cardiovascular Institute has evolved into an international leader in breakthrough research, advanced technology and exceptional patient care. This report reflects on two decades of innovation, while looking ahead to the next chapter. Read our annual report below.
|
A Second Chance at Life
Northwestern Medicine Cardiology and Cardiac Surgery teams collaborated with the Tumor Board to remove a rare, football sized heart tumor. Hear Mike’s story. |
|
January 2026 Join Anita W. Asgar, MD, and Jyothy J. Puthumana, MD, in the Cardiac Catheterization Lab as they perform a MitraClip™ procedure on a clinically complex patient with severe mitral regurgitation.
|
|
Featuring: Baljash S. Cheema, MD
|
December 2025 Featuring: Mohamed Al-Kazaz, MD
|
|
Featuring: Quentin R. Youmans, MD, MSc
|
Featuring: Kevin E. Hodges, MD
|
Featuring: Sanjiv J. Shah, MD
|
|
TWIST EFS Early Feasibility Study is enrolling adult patients with symptomatic moderate-severe and severe, mitral regurgitation (MR) who are at elevated risk for surgical mitral valve repair or replacement. Eligible participants will receive the INNOVALVE Transseptal Mitral Valve Replacement (TMVR) System (study device) which is designed to reduce the amount of mitral regurgitation without the need for surgery (less invasive).
|
JOURNEY The purpose of this study is to assess the safety of the J-Valve Transfemoral (TF) System in patients presenting with symptomatic, severe aortic valve regurgitation (AR) who are judged by a multi-disciplinary heart team to be at high risk for open surgical aortic valve replacement (SAVR). The J-Valve is intended to replace the native aortic heart valve via a minimally invasive transcatheter approach without removing the native valve. Eligible participants will receive the investigational valve and be followed for 5 years.
Principal Investigator:
Anita W. Asgar, MD |
|
About Us Terms of Use Privacy Policy How to Vote for U.S. News & World Report Best Hospitals
© 2026 Northwestern Medicine® and Northwestern Memorial HealthCare. Northwestern Medicine® is a trademark of Northwestern Memorial HealthCare, used by Northwestern University |